- Metal extracting agent containing sulfoxide group and preparation method thereof
-
The invention discloses a metal extracting agent containing a sulfoxide group and a preparation method thereof. The metal extracting agent containing the sulfoxide group is 2-(alkylsulfinyl)-N-((tetrahydrofuran-2-yl)methyl)acetamide. According to the preparation method, thioalcohol is used as a raw material, reacts with chloroacetic acid in an alkaline condition to generate corresponding thioether; afterwards, the corresponding thioether is oxidized through hydrogen peroxide in an organic-acid environment to obtain sulfoxide; the sulfoxide reacts with 2-tetrahydrofurfuryl amine in highly-acidic and high-temperature conditions, so as to generate corresponding amide. The metal extracting agent containing the sulfoxide group, which is provided by the invention, is high in the safety to an environment and an organism, is low-toxicity, is good in wettability, high in foaming capacity and liable in biodegradation, and has quite good extraction effects on rare earth metals thulium, ytterbium and lutetium in a weakly acidic condition.
- -
-
Paragraph 0050; 0051; 0052
(2017/07/04)
-
- The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism
-
Thio-ether fatty acids (THEFAs), including the parent 2-(tetradecylthio)acetic acid (TTA), are modified fatty acids (FAs) that have profound effects on lipid metabolism given that they are blocked for β-oxidation, and able to act as peroxisome proliferator-activated receptor (PPAR) agonists. Therefore, TTA in particular has been tested clinically for its therapeutic potential against metabolic syndrome related disorders. Here, we describe the preparation of THEFAs based on the TTA scaffold with either a double or a triple bond. These are tested in cultured human skeletal muscle cells (myotubes), either as free acid or following esterification as phospholipids, lysophospholipids or monoacylglycerols. Metabolic effects are assessed in terms of cellular bioavailabilities in myotubes, by FA substrate uptake and oxidation studies, and gene regulation studies with selected PPAR-regulated genes. We note that the inclusion of a triple bond promotes THEFA-mediated FA oxidation. Furthermore, esterification of THEFAs as lysophospholipids also promotes FA oxidation effects. Given that the apparent clinical benefits of TTA administration were offset by dose limitation and poor bioavailability, we discuss the possibility that a selection of our latest THEFAs and THEFA-containing lipids might be able to fulfill the therapeutic potential of the parent TTA while minimizing required doses for efficacy, side-effects and adverse reactions.
- Lund, Jenny,Stensrud, Camilla,Rajender,Bohov, Pavol,Thoresen, G. Hege,Berge, Rolf K.,Wright, Michael,Kamal, Ahmed,Rustan, Arild C.,Miller, Andrew D.,Skorve, Jon
-
p. 1191 - 1203
(2016/03/01)
-
- NATURAL LIPIDS CONTAINING NON-OXIDIZABLE FATTY ACIDS
-
Provided herein is technology relating to natural lipids containing non-β-oxidizable fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of natural lipids containing non-β-oxidizable fatty acids.
- -
-
Paragraph 00324-00328
(2016/02/18)
-
- Sulfur makes the difference: Synthesis and mesomorphic properties of novel thioether-functionalized imidazolium ionic liquid crystals
-
Novel thioether-linked imidazolium ionic liquid crystals were synthesized starting from methyl 2-mercaptoacetate. The mesomorphic properties were determined by differential scanning calorimetry (DSC), polarizing optical microscopy (POM), and X-ray diffraction. All mesogens displayed smectic A mesophase geometries with strongly interdigitated bilayer structures. Comparison of the thioether-linked imidazolium salts with the corresponding amine- and amide-linked imidazolium salts as well as simple N-alkyl-imidazolium salts showed that both mesophase width and stability increased with increasing softness of the linking unit, thus indicating the beneficial effect of sulfur. Additionally, an increase of the length of the linking unit decreased the interdigitation of the alkyl chains.
- Mansueto, Markus,Kre?, Katharina Christina,Laschat, Sabine
-
p. 6258 - 6264
(2015/03/30)
-
- Synthesis and characterization of some novel higher C,N-diphenyl nitrones, isoxazolines, and mercaptobenzimidazoles as oleochemicals
-
Some novel long-chain nitrones, isoxazolines, and (1H-benzo[d]-imidazol-2- ylthio) derivatives were synthesized. Nitrones, N-{4-[2-(tetradecylthio)acetoxy] benzylidene}aniline oxide, and N-[4-(12-oxo-2,5,8,11-tetraoxadocosan-22-yloxy) benzylidene]aniline oxide were prepared via the reaction of -phenylhydroxylamine with the corresponding aromatic aldehydes. The isoxazolines were prepared from undec-10-en-1-ol and benzonitrile-N-oxide which was generated in situ. The 1H-benzo[d]-imidazol-2-ylthio derivatives were synthesized via the replacement reaction of -bromo esters and 2-mercaptobenzimidazole.
- Yldrm,Cetin
-
experimental part
p. 952 - 964
(2012/08/07)
-
- Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome
-
Tetradecylthioacetic acid (TTA) 1 is a peroxisome proliferator-activated receptor (PPAR) agonist found to improve insulin sensitivity, lower blood lipid levels, enhance fatty acid oxidation, and promote anti-inflammation in vivo. In an attempt to enhance these properties, two key thioether fatty acid (Thefa) lipids, ditetradecylthioacetyl phosphatidylcholine 2 and tritetradecylthioacetyl glycerol 3, are synthesized and administered po to male Wistar rats at two different doses to study and compare metabolic outcomes relative to the administration of 1 alone after 6 days. Liposomal formulations of 1 and 2 are also prepared to evaluate acute metabolic responses (at 3 h) post iv injection. Across all metrics measured, 1-induced responses post po administration are in line with previous data. Responses induced from 3 are mostly equivalent to 1-induced responses. By contrast, 2-induced responses almost always outperform those of 1 and 3. Therefore, 2 may represent a new lead for the treatment of metabolic syndrome.
- Jorgensen, Michael R.,Bhurruth-Alcor, Yushma,R?st, Therese,Bohov, Pavol,Müller, Melanie,Guisado, Cristina,Kostarelos, Kostas,Dyr?y, Endre,Berge, Rolf K.,Miller, Andrew D.,Skorve, Jon
-
experimental part
p. 1172 - 1179
(2009/12/24)
-
- Acylated aminopropanediols and analogues and therapeutic uses thereof
-
The invention relates to novel acylated aminopropanediols and the nitrogen and sulfur analogues thereof, pharmaceutical compositions comprising same, therapeutic uses thereof, in particular for the treatment of cerebral ischemia. The invention also provides a method of preparing said derivatives.
- -
-
Page/Page column 20
(2008/06/13)
-
- Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof
-
The invention relates to the use of acyl glycerols and the nitrogen- and sulfur-containing analogues thereof in the therapeutic field, particularly in human health. The inventive compounds have advantageous pharmacological properties and are particularly of use for the prevention or treatment of neurodegenerative diseases.
- -
-
Page/Page column 25
(2008/06/13)
-
- Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f
-
The invention relates to the use of molecules, particularly in the fields of human and veterinary health and cosmetics. The inventive compounds are acylated aminopropanediols and the nitrogen- and sulfur-containing analogues thereof and have advantageous pharmacological and cosmetic properties. In particular, the inventive compounds can be used to prevent and/or treat dyslipidemias, cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, some cancers, dermatological diseases, and, in the field of cosmetics, to combat skin ageing and the effects of same, in particular the development of wrinkles and the like.
- -
-
Page/Page column 22
(2008/06/13)
-
- Therapeutic use of of acyglycerols and the nitrogen-and sulphur-containing analogues thereof
-
The invention relates to the use of acylglycerols and the nitrogen- and sulfur-containing analogues thereof in therapy, particularly for the treatment of cerebral ischemia. The invention further relates to methods for preparing said derivatives, novel compounds, in particular acylglycerols, the nitrogen- and sulfur-containing analogues thereof and methods for preparing same.
- -
-
Page/Page column 9-10
(2010/11/24)
-
- Fatty acid compounds, preparation and uses thereof
-
The invention concerns novel molecules, their preparation and their uses, in particular in the field of human and veterinary medicine and cosmetics. The inventive compounds are partly fatty acid derivatives and exhibit advantageous pharmacological and cosmetic properties. The invention also concerns various uses of said compounds, the pharmaceutical compositions containing them and methods for preparing them. The inventive compounds are useful in particular for preventing and/or treating dyslipidemiae, cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, certain cancers, dermatological diseases and in cosmetics, for fighting against skin aging and its effects notably against wrinkles and the like
- -
-
-
- Anti-cancer nitro- and thia-fatty acids
-
The present invention relates to pharmaceutical compositions comprising, as an anti-cancer agent: (a) one or more compounds having the formula NO2-A-B, wherein A is a saturated or unsaturated hydrocarbon chain of 14-26 double bonds, and B is (CH2)m(COOH)n in which n is a integer from 0 to 2 and m is an integer from 0 to 2; or a derivative thereof in which the hydrocarbon chain has one or more than one substitution selected from the group consisting of hydroxy, hydroperoxy, epoxy and peroxy; (b) one or more compounds selected from polyunsaturated fatty acids (PUFA's) having a 16 to 26 carbon atom chain and 3 to 16 double bonds, and wherein the PUFA is covalently coupled at the carboxylic acid group to an amino acid selected from glycine and aspartic acid; (c) one or more compounds selected from unsaturated fatty acids having an 18 to 25 carbon atom chain and 1 to 6 double bonds and wherein the fatty acid has one or two beta-oxa, gamma-oxa, beta-thia, gamma-thia substitutions: or (d) one or more compounds having formula (I) wherein A' is a saturated or unsaturated hydrocarbon chain of 9-26 carbon atoms, X is oxygen or is absent and B' is (CH2)J(COOH)k in which j is an integer from 1 to 3 and K is 0 or 1; or a derivative thereof in which the hydrocarbon chain has one or more than one substitution selected from the group consisting of hydroxy, hydroperoxy, epoxy and peroxy; and a pharmaceutically acceptable carrier or diluent.
- -
-
-
- SULFUR-CONTAINING PHOSPHOLIPID DERIVATIVES
-
The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X-Y-Z-, wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO2, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula -[C(O)]mPHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.
- -
-
-
- Antioxidant behaviour of thia fatty acids
-
Eight thia fatty acids and other sulfides have been studied as inhibitors of autoxidation of arachidonic acid. The inhibitors extend the lag phase of the oxidation, to varying degrees. A carboxyl group in the vicinity of the sulfur reduces the antioxidant activity, while unsaturated sulfides are more effective than their saturated analogues. The results are consistent with the sulfides acting to reduce fatty acid hydroperoxides, which otherwise accumulate during the early stages of reaction and propagate the free-radical oxidation process.
- Easton, Christopher J.,Ferrante, Antonio,Robertson, Thomas A.,Xia, Ling
-
p. 647 - 653
(2007/10/03)
-
- Treatment of skin conditions by use of PPAR alpha activators
-
Disorders of the skin and mucous membrane that have a disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of compounds that are either activators of the farnesoid X receptor, activators of the peroxisome proliferator-activated receptor alpha , and oxysterol activators of the LXR alpha receptor. The same compounds are also effective in treating disorders of epidermal differentiation and proliferation.
- -
-
-
- Sufrace-Active Properties and Thermal Behavior of S-Alkylthio-Carboxylic Acids and Their Potassium Salts
-
S-Alkylthiocarboxylic acids and their potassium salts were prepared by photoaddition of α-olefins (C10, C12, and C14) with mercapto carboxylic acids such as thiomalic acid, triopropionic acid, and thioglycolic acid.The physicochemical solution properties and thermal stabilities for three series of thiosurfactants were evaluated.S-Alkylthiocarboxylic acids that contain bridged S-bonds provide excellent thermally stable surfactants, and their alkaline salts exhibit good surface activity.KEY WORDS: α-Olefin, mercapto carboxylic acid, photoaddition, S-alkylthiocarboxylic acid, S-alkylthioglycolic acid, S-alkylthiomalic acid, S-alkylthiopropionic acid, surface activity, thermal stability.
- Kamio, Katsuhisa,Kamata, Kohro,Mima, Seiji,Kuroda, Toshiharu,Ookawara, Hiroshi,et al.
-
p. 805 - 810
(2007/10/02)
-
- Non-β-oxidizable fatty acid analogues with the effect to reduce the concentration of cholesterol and triglycerides in blood of mammals
-
A method is provided for the treatment of hypolipaemic conditions and for reducing the concentration of cholesterol and triglycerides in the blood of mammals. The method comprises administering to a mammal an effective amount of non-β-oxidizable fatty acid analogue of the formula Alkyl-X-CH2 COOR where the alkyl group is a saturated or unsaturated hydrocarbon chain of 8 to 22 carbon atoms, where X represents an oxygen atom, a sulfur atom, a sulfoxide (SO) or sulfone (SO2) group and where R is a hydrogen atom or an alkyl group of 1 to 4 carbon atoms. Pharmaceutical compositions are also provided.
- -
-
-
